"10.1371_journal.pone.0063940","plos one","2013-05-16T00:00:00Z","Donglin Liu; Chien-Hsing Chang; Edmund A Rossi; Thomas M Cardillo; David M Goldenberg","IBC Pharmaceuticals, Inc., Morris Plains, New Jersey, United States of America; Immunomedics, Inc., Morris Plains, New Jersey, United States of America; Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, New Jersey, United States of America","Conceived and designed the experiments: CHC DL TMC. Performed the experiments: DL. Analyzed the data: DL CHC EAR DMG TMC. Wrote the paper: DL CHC EAR DMG.","Donglin Liu, Chien-Hsing Chang, Edmund A. Rossi, Thomas M. Cardillo and David M Goldenberg are employees of both Immunomedics, Inc., and IBC Pharmaceuticals, Inc. (a wholly owned subsidiary of Immunomedics, Inc.) All authors have stock, and/or stock options with Immunomedics Inc.; CHC, EAR and DMG have stock and/or stock options with IBC Pharmaceuticals Inc. For this study humanized antibodies including veltuzumab (anti-CD20), hRS7 (anti-Trop2), hMN-15 (anti-CEACAM6), and hL243 (anti-HLADR) were provided by Immunomedics, Inc. One or more US and/or foreign patent applications (Title-Targeting IFN-lambda1 with antibodies potently enhances both anti-tumor and anti-viral activities, Numbers-PCT/US13/23093 and 13/749,985) have been filed on the subject matter of the manuscript; however, this does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","05","Donglin Liu","DL",5,TRUE,3,1,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
